MARKET

BCLI

BCLI

Brainstorm Cell
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.250
-0.070
-2.11%
Opening 15:57 01/20 EST
OPEN
3.310
PREV CLOSE
3.320
HIGH
3.410
LOW
3.200
VOLUME
73.00K
TURNOVER
--
52 WEEK HIGH
8.14
52 WEEK LOW
2.750
MARKET CAP
117.90M
P/E (TTM)
-3.7769
1D
5D
1M
3M
1Y
5Y
BrainStorm Cell Therapeutics to Present at Biotech Showcase™ 2022
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Ralph Kern, M.D. MHSc, President and Chief Medical Officer of Brainstorm Cell Therapeutics, will prov...
PR Newswire · 01/04 12:00
FDA authorizes further dosing of BrainStorm Cell's NurOwn under expanded access program
BrainStorm Cell Therapeutics (NASDAQ:BCLI) announces plans for a dosing extension of NurOwn for participants who completed the Expanded Access Protocol (EAP). BCLI shares up 6.2% premarket at $3.95. The FDA recommended that
Seekingalpha · 12/27/2021 13:00
BRIEF-FDA Authorizes Further NurOwn® Dosing Under Expanded Access Program
reuters.com · 12/27/2021 12:05
BrainStorm Cell Therapeutics Announces FDA Authorizes Further NurOwn Dosing Under Expanded Access Program
BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced plans for a dosing extension of NurOwn® for participants who completed the
Benzinga · 12/27/2021 12:02
FDA Authorizes Further NurOwn® Dosing Under Expanded Access Program
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced plans for a dosing extension of NurOwn® for participants who completed the Expanded Access Protocol (EAP). The U.S. ...
PR Newswire · 12/27/2021 12:00
BCLI: Phase 3 ALS Results Published in Muscle and Nerve…
By David Bautz, PhD NASDAQ:BCLI READ THE FULL BCLI RESEARCH REPORT
Benzinga · 12/18/2021 14:30
20 Stocks Moving in Tuesday's Pre-Market Session
Gainers MIND Technology, Inc. (NASDAQ: MIND) rose 37.2% to $1.88 in pre-market trading after the company reported it entered into a Cooperative Research and Development Agreement with the United States Navy's Naval Surface Warfare Center, Panama City Divis...
Benzinga · 12/14/2021 11:50
BRIEF-Brainstorm Cell Therapeutics Announces Peer Reviewed Publication Of Nurown's® Phase 3 Study For ALS
reuters.com · 12/13/2021 12:25
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BCLI. Analyze the recent business situations of Brainstorm Cell through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
50.00%Buy
50.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average BCLI stock price target is 11.00 with a high estimate of 14.00 and a low estimate of 8.00.
High14.00
Average11.00
Low8.00
Current 3.250
EPS
Actual
Estimate
-0.34-0.26-0.17-0.09
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 71
Institutional Holdings: 5.24M
% Owned: 14.44%
Shares Outstanding: 36.28M
TypeInstitutionsShares
Increased
8
387.85K
New
5
167.34K
Decreased
25
788.49K
Sold Out
10
262.09K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.76%
Pharmaceuticals & Medical Research
-0.62%
Key Executives
Chairman/Independent Director
Jacob Frenkel
President
Ralph Kern
Chief Executive Officer
Chaim Lebovits
Vice Chairman/Independent Director
Irit Arbel
Chief Financial Officer
Alla Patlis
Chief Operating Officer/Executive Vice President
David Setboun
Executive Vice President/Secretary/Director
Uri Yablonka
Executive Vice President
Stacy Lindborg
Executive Vice President
Anthony Waclawski
Other
Arturo Araya
Director
Menghisteab Bairu
Independent Director
June Almenoff
Independent Director
Anthony Polverino
Independent Director
Malcolm Taub
No Data
  • All
  • Financials
  • Insiders
More
About BCLI
Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is focused on development of cellular therapies for the treatment of neurodegenerative diseases, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Progressive Multiple Sclerosis (PMS), Alzheimer's disease (AD) and other neurodegenerative diseases. The Company offers its services through NurOwn platform. Its BrainStorm Cell Therapeutics Ltd. (Israeli Subsidiary) holds rights to commercialize the technology, NurOwn. Its NurOwn platform leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells (MSCs) to secrete high levels of neurotrophic factors (NTFs), modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function.

Webull offers kinds of Brainstorm Cell Therapeutics Inc stock information, including NASDAQ:BCLI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCLI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BCLI stock methods without spending real money on the virtual paper trading platform.